Mostrar registro simples

dc.contributor.authorTorres Dueñas, Nidia Alexandra
dc.contributor.authorÁlvarez Moreno, Carlos Arturo
dc.contributor.authorRondón Sepulveda, Martin Alonso
dc.date.accessioned2020-04-27T21:19:39Z
dc.date.accessioned2020-05-08T15:26:50Z
dc.date.accessioned2023-05-11T19:35:50Z
dc.date.available2020-04-27T21:19:39Z
dc.date.available2020-05-08T15:26:50Z
dc.date.available2023-05-11T19:35:50Z
dc.date.created2009
dc.identifierhttps://scielo.conicyt.cl/pdf/rci/v26n2/art04.pdfspa
dc.identifier.issn0716-1018 / 1609-7203 (Electrónico)spa
dc.identifier.urihttps://hdl.handle.net/20.500.12032/116899
dc.description.abstractThe frequency of invasive mycosis caused by Candida sp has increased significantly in immuno-compromised patients and in those under medical/surgical treatment; along with it, the use of azoles has fostered resistance. Objective: To compare in vitro susceptibility techniques, susceptibility to fluconazol was determined by the M27-A2 method of CLSI (Clinical Laboratory Standard Institute), the disk diffusion technique in 90 invasive Candida sp isolated species (49 C albicans, 30 C. tropicalis, 5 C parapsilosis, 4 C. guilliermondii and 2 C. lusitaniae) and the E-test in 16 isolated. Results: Over 90% of strains were susceptible to fluconazol. A straight correlation between disk-diffusion technique and the E-test was observed regarding the reference method (0.944 and 0.938, respectively). Conclusión: In our institution the use of fluconazol for invasive candidiasis is recommended, as well as the routine use of the disk-diffusion or E-test techniques in high complex hospitals in Colombia.spa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.languagespaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceRevista chilena de infectología; Vol. 26 Núm. 2 (2009)spa
dc.subjectCandidaspa
dc.subjectFluconazolespa
dc.subjectPruebas de susceptibilidad antifúngicaspa
dc.titleEvaluación mediante tres técnicas de susceptibilidad a fluconazol en especies de Candida aisladas en pacientes con infecciones invasoras. Bogotá - Colombiaspa
dc.typeinfo:eu-repo/semantics/article


Arquivos deste item

ArquivosTamanhoFormatoVisualização
art04(1).pdf172.0Kbapplication/pdfVisualizar/Abrir

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples

http://creativecommons.org/licenses/by-nc/4.0/
Exceto quando indicado o contrário, a licença deste item é descrito como http://creativecommons.org/licenses/by-nc/4.0/

© AUSJAL 2022

Asociación de Universidades Confiadas a la Compañía de Jesús en América Latina, AUSJAL
Av. Santa Teresa de Jesús Edif. Cerpe, Piso 2, Oficina AUSJAL Urb.
La Castellana, Chacao (1060) Caracas - Venezuela
Tel/Fax (+58-212)-266-13-41 /(+58-212)-266-85-62

Nuestras redes sociales

facebook Facebook

twitter Twitter

youtube Youtube

Asociaciones Jesuitas en el mundo
Ausjal en el mundo AJCU AUSJAL JESAM JCEP JCS JCAP